相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
Lee-Lee Lai et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Mechanisms and Characteristics of Sulfonylureas and Glinides
Wei Lv et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
The active nuclear form of SREBP1 amplifies ER stress and autophagy via regulation of PERK
Qin Hu et al.
FEBS JOURNAL (2020)
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
Masanori Shimizu et al.
DIABETES OBESITY & METABOLISM (2019)
Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
Ryo Goto et al.
FEBS OPEN BIO (2019)
Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Massand Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Yoshitaka Arase et al.
CLINICAL DRUG INVESTIGATION (2019)
Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice
Kazuno Omori et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
Teruo Jojima et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
Norio Akuta et al.
HEPATOLOGY RESEARCH (2019)
Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
Ji-Won Kim et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Mitsuko Inoue et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
Ichiro Nakamura et al.
ADVANCES IN THERAPY (2019)
Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model
Masafumi Yamane et al.
YONAGO ACTA MEDICA (2019)
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results)
Hiromi Tabuchi et al.
ENDOCRINE JOURNAL (2019)
Thiazolidinediones as antidiabetic agents: A critical review
M. J. Nanjan et al.
BIOORGANIC CHEMISTRY (2018)
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel et al.
CELL METABOLISM (2018)
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
David Hojland Ipsen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
Noboru Kurinami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson et al.
DIABETOLOGIA (2018)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation
Soad L. Kabil et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
Leigh Goedeke et al.
HEPATOLOGY (2018)
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Toshio Itani et al.
OBESITY SCIENCE & PRACTICE (2018)
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study
Takashi Shibuya et al.
DIABETES OBESITY & METABOLISM (2018)
Role of inflammatory response in liver diseases: Therapeutic strategies
Jose A. Del Campo et al.
WORLD JOURNAL OF HEPATOLOGY (2018)
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
Ji Hye Han et al.
DIABETOLOGIA (2017)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Akio Ohta et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
Piangkwan Sa-nguanmoo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Yuliya Lytvyn et al.
CIRCULATION (2017)
CENTRAL DIABETES INSIPIDUS: CLINICAL CHARACTERISTICS AND LONG-TERM COURSE IN A LARGE COHORT OF ADULTS
Hiba Masri-Iraqi et al.
ENDOCRINE PRACTICE (2017)
The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus
Yukihiro Bando et al.
DIABETOLOGY INTERNATIONAL (2017)
Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Schohraya Spahis et al.
ANTIOXIDANTS & REDOX SIGNALING (2017)
Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies
Norio Akuta et al.
HEPATOLOGY COMMUNICATIONS (2017)
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Francis W. B. Sanders et al.
BIOLOGICAL REVIEWS (2016)
Molecular mechanisms regulating NLRP3 inflammasome activation
Eun-Kyeong Jo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
Romina Bertinat et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
The phosphorylation-dependent regulation of nuclear SREBP1 during mitosis links lipid metabolism and cell growth
Maria Teresa Bengoechea-Alonso et al.
CELL CYCLE (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment
Meric Erikci Ertunc et al.
JOURNAL OF LIPID RESEARCH (2016)
Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease
Sabina Paglialunga et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes
M. Kusunoki et al.
DRUG RESEARCH (2016)
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Elisa Benetti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions
Naoki Shimo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance
Dov B. Ballak et al.
CYTOKINE (2015)
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Itay Raphael et al.
CYTOKINE (2015)
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient L-amino acid-defined diet in rats
Yuka Hayashizaki-Someya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management
Sara Blasco-Algora et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Benjamin M. Leon et al.
WORLD JOURNAL OF DIABETES (2015)
Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice
Angela M. Hall et al.
DIABETES (2014)
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Alexander Wree et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Non-alcoholic fatty liver disease
Naveed Sattar et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Pathophysiology of NASH: Perspectives for a Targeted Treatment
Fabio Marra et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus
L. H. Chen et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Computed Tomography Scans in the Evaluation of Fatty Liver Disease in a Population Based Study: The Multi-Ethnic Study of Atherosclerosis
Irfan Zeb et al.
ACADEMIC RADIOLOGY (2012)
Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver
Angela M. Hall et al.
JOURNAL OF LIPID RESEARCH (2012)
Mechanism of lipid induced insulin resistance: Activated PKCε is a key regulator
Suman Dasgupta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Discovery of non-glucoside SGLT2 inhibitors
An-Rong Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease
Nishanth E. Sunny et al.
CELL METABOLISM (2011)
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2
Francois R. Jornayvaz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
PLASMA LEVELS OF VITAMIN E AND CAROTENOIDS ARE DECREASED IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
A. Erhardt et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2011)
Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice
Hirokazu Sugimoto et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2010)
Thiadiazole-based Thioglycosides as Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors
Gao Yunlong et al.
CHINESE JOURNAL OF CHEMISTRY (2010)
Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism
Yuguang Shi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2
William N. Washburn
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
Cheol Soo Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Hepatic histology in obese patients undergoing bariatric surgery
Mariana Machado et al.
JOURNAL OF HEPATOLOGY (2006)
Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1
GQ Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
HB El-Serag et al.
GASTROENTEROLOGY (2004)
Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity
JM Ntambi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation
M Cnop et al.
DIABETES (2001)
分享论文
